1. Scrip

GSK Lifted By $2.2bn Zantac Litigation Deal

 
• By Andrew McConaghie

The payout will bring GSK closer to resolving lawsuits which have occupied it for years – though investors are now likely to focus on new product growth concerns at the UK firm.

New GSK sign
• Source: Shutterstock

GSK’s share price surged by 6% after it announced a multi-billion dollar deal to settle most of the remaining Zantac-related lawsuits against it.

Key Takeaways

  • GSK and other companies have faced lawsuits since the US FDA called for ranitidine products to be removed from the market in 2020.

The company has agreed to pay $2.2bn to settle around 80,000 outstanding US-based liability cases alleging that Zantac (ranitidine) caused...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

AstraZeneca Taps Into China’s R&D Engine With CSPC Alliance

 
• By Andrew McConaghie

After in-licensing a cardiovascular candidate last year, AstraZeneca has signed a strategic drug discovery alliance, which could generate billions of dollars in payments to the Chinese firm.

Executives On The Move: New CMOs At Instil Bio, Nkarta & Catalyst Pharma

Recent moves in the industry include changes at the top at iOnctura and Orca Bio, plus Sutro Biopharma, Tenpoint Therapeutics and Helix BioPharma get new CFOs.

In Brief: Starton Moves Low-Dose Lenalidomide To Phase IIa For Multiple Myeloma

 
• By Sushmita Panda

Study to add to safety and tolerability data for infused formulation and may help identify optimal dose for future pivotal trial.